此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Phase I/II, Dose-Escalation and Dose-Expansion Study of CS5006, in Participants With Advanced Solid Tumors

2026年11月10日 更新者:CStone Pharmaceuticals

A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors

This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.

研究概览

地位

尚未招聘

干预/治疗

详细说明

In Phase I, participants with specified advanced epithelial solid tumors will be enrolled to establish the MTD, if any, and tentative RP2D(s) of CS5006. The specified advanced epithelial solid tumors included but not limited non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of head and neck (HNSCC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), cervical cancer (CC), esophageal squamous cell carcinoma (ESCC) , endometrial cancer, ovarian cancer (OC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), gastric cancer (GC), pancreatic cancer(PDAC) and prostate cancer(PCa).

In Phase II, participants with selected advanced solid tumors - including locally advanced or metastatic non-small cell lung cancers (AGA [actionable genomic alterations] negative NSCLC, Cohort 1; EGFR-mutant NSCLC, Cohort 2; NSCLC with actionable driver alterations other than EGFR-sensitive mutations, Cohort 3; colorectal cancer (CRC), Cohort 4; squamous cell carcinoma of head and neck (HNSCC), Cohort 5; urothelial carcinoma (UC), Cohort 6; cervical cancer (CC), Cohort 7; esophageal squamous cell carcinoma (ESCC), Cohort 8 - will be enrolled to further assess the efficacy, safety, tolerability, pharmacokinetics of CS5006 at the tentative RP2D(s).

研究类型

介入性

注册 (估计的)

310

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200123
        • Shanghai East Hospital
        • 首席研究员:
          • Caicun Zhou
    • New South Wales
      • North Ryde、New South Wales、澳大利亚、2109
        • Macquarie University
        • 首席研究员:
          • John Park, Dr
      • Randwick、New South Wales、澳大利亚、2031
        • Scientia Clinical Research Ltd
        • 首席研究员:
          • Charlotte lemech, Dr
    • Victoria
      • Clayton、Victoria、澳大利亚、3168
        • Monash Medical Centre
        • 首席研究员:
          • Sophia Frentzas, Dr

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Evidence of a personally signed and dated informed consent document.
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  • Being ≥ 18 years of age on the day of signing informed consent.
  • Pathologically or cytologically confirmed, unresectable advanced solid tumors.
  • Participants must have at least one measurable lesion according to RECIST Version1.1.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
  • Adequate organ function.
  • Life expectancy ≥ 3 months.
  • Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after the last study drug administration

Exclusion Criteria:

  • Has disease that is suitable for local treatment administered with curative intent.
  • Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
  • Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is symptomatic, untreated, or requires therapy.
  • Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
  • Has uncontrolled pleural effusion, pericardial effusion, or ascites.
  • Has immune deficient disease or received systemic immunosuppressive treatment.
  • Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
  • Has history of (non-infectious) interstitial lung disease/pneumonitis that required steroids.
  • Has active infections requiring systemic therapy.
  • Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
  • Insufficient washout from prior anti-tumor therapy.
  • Received live vaccine within 28 days prior to first dose.
  • History of allogeneic organ or hematopoietic stem cell transplantation.
  • History of hypersensitivity to excipients of study drug or any monoclonal antibody.
  • Any toxic effects of prior therapy unresolved to Grade ≤1.
  • Pregnant or breastfeeding women.
  • Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose Escalation

Participants will be administered escalating doses of CS5006.

CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

实验性的:Dose Expansion

Participants will be administered the recommended dose(s) of CS5006 according to dose-escalation data.

CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
[剂量扩展] 研究人员根据 RECIST v1.1 评估客观缓解率 (ORR)
大体时间:最长约 2 年
最长约 2 年
[Dose Escalation] The incidence and severity of adverse events (AEs)
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation] Maximum tolerated dose (MTD) of CS5006
大体时间:Cycle 1 (Up to 21 Days)

Participants will receive CS5006 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT).

Cycle 1 (Up to 21 Days)
[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006
大体时间:Up to approximately 2 years

The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range.

Up to approximately 2 years

次要结果测量

结果测量
大体时间
[剂量递增] 研究人员根据 RECIST v1.1 评估客观缓解率 (ORR)
大体时间:最长约 2 年
最长约 2 年
[Dose Escalation & Expansion] Area under the curve (AUC) of CS5007
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Duration of response (DOR) evaluated by investigators per RECIST v1.1
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Disease control rate (DCR) evaluated by investigators per RECIST v1.1
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Expansion] The incidence and severity of adverse events (AEs)
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Maximum concentration (Cmax) of CS5006
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Time to maximum concentration (Tmax) of CS5006
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Elimination half-life (t1/2) of CS5006
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Clearance (CL) of CS5006
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Volume of distribution (Vz) of CS5006
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Trough concentration (Ctrough) of CS5006
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Accumulation ratio (R) of CS5006
大体时间:Up to approximately 2 years
Up to approximately 2 years
[Dose Escalation & Expansion] Number of participants with anti-CS5006 antibodies
大体时间:Up to approximately 2 years
Up to approximately 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2029年7月1日

研究完成 (估计的)

2029年7月1日

研究注册日期

首次提交

2026年11月10日

首先提交符合 QC 标准的

2026年11月10日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • CS5006-101

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅